Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saul Genuth

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Diabetes Care|November 25, 2003
Lowering the criterion for impaired fasting glucose is in orderSaul Genuth
Diabetes Care|May 23, 2015
Response to comment on Genuth. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on! Diabetes Care 2015;38:170-175Saul Genuth
Diabetes Care|December 25, 2014
Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on!Saul Genuth
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 22, 2006
Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetesSaul Genuth
Diabetes Care|May 30, 2008
A step backward--or is it forward?Saul Genuth, Richard Kahn
Diabetes Care|December 21, 2013
The diabetes control and complications trial/epidemiology of diabetes interventions and complications study: 30th anniversary presentationsBernard Zinman, Saul Genuth, David M Nathan
Glycoconjugate Journal|June 26, 2016
The pecking order of skin Advanced Glycation Endproducts (AGEs) as long-term markers of glycemic damage and risk factors for micro- and subclinical macrovascular disease progression in Type 1 diabetesVincent M Monnier, Saul Genuth, David R Sell
Diabetes Care|December 24, 2004
Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes: response to McCarter et alSaul Genuth, John M Lachin, David M Nathan
Annals of the New York Academy of Sciences|July 23, 2005
Glycation products as markers and predictors of the progression of diabetic complicationsVincent M Monnier, David R Sell, Saul Genuth
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|March 31, 2010
Effect of dexamethasone on oral glucose tolerance in healthy adultsDima Abdelmannan, Rundsara Tahboub, Saul Genuth, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Diabetes Care|November 25, 2003
Lowering the criterion for impaired fasting glucose is in orderSaul Genuth
Diabetes Care|May 23, 2015
Response to comment on Genuth. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on! Diabetes Care 2015;38:170-175Saul Genuth
Diabetes Care|December 25, 2014
Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on!Saul Genuth
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 22, 2006
Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetesSaul Genuth
Diabetes Care|May 30, 2008
A step backward--or is it forward?Saul Genuth, Richard Kahn
Diabetes Care|December 21, 2013
The diabetes control and complications trial/epidemiology of diabetes interventions and complications study: 30th anniversary presentationsBernard Zinman, Saul Genuth, David M Nathan
Glycoconjugate Journal|June 26, 2016
The pecking order of skin Advanced Glycation Endproducts (AGEs) as long-term markers of glycemic damage and risk factors for micro- and subclinical macrovascular disease progression in Type 1 diabetesVincent M Monnier, Saul Genuth, David R Sell
Diabetes Care|December 24, 2004
Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes: response to McCarter et alSaul Genuth, John M Lachin, David M Nathan
Annals of the New York Academy of Sciences|July 23, 2005
Glycation products as markers and predictors of the progression of diabetic complicationsVincent M Monnier, David R Sell, Saul Genuth
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|March 31, 2010
Effect of dexamethasone on oral glucose tolerance in healthy adultsDima Abdelmannan, Rundsara Tahboub, Saul Genuth, et al.
Pageof 6